Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
- 1 March 1997
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 349 (9052), 589-593
- https://doi.org/10.1016/s0140-6736(96)09377-4
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissuesClinical Immunology and Immunopathology, 1992
- MS: a CNS and systematic autoimmune diseaseImmunology Today, 1989
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR MYASTHENIA GRAVISThe Lancet, 1984
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983